Document:

IVR-2014.12.31-10Kexhibit - 10.7

Exhibit 10.7

SECOND AMENDMENT TO
FIRST AMENDED AND RESTATED AGREEMENT
 OF LIMITED PARTNERSHIP OF
IAS OPERATING PARTNERSHIP LP

The undersigned, as the General Partner of IAS Operating Partnership LP (the “Partnership”), hereby amends the Partnership’s First Amended and Restated Agreement of Limited Partnership, as heretofore amended (the “Partnership Agreement”), pursuant to Sections 4.3.A, 4.3.B and 7.3.C of the Partnership Agreement, to replace the term “IAS Partnership Units” in Section 4.3.B with “Limited Partner Partnership Units”, amend the current Exhibit A to read as provided in the attached Exhibit A and add a new Exhibit F to read as provided in the attached Exhibit F.  In all other respects, the Partnership Agreement shall continue in full force and effect as amended hereby.  Any capitalized terms used in this Amendment and not defined herein have the meanings given to them in the Partnership Agreement.

Dated:  September 14, 2014        IAS OPERATING PARTNERSHIP LP

By:    INVESCO MORTGAGE CAPITAL INC., 
general partner

By:   /s/ Robert H. Rigsby                     
        Name: Robert H. Rigsby
        Title:   Vice President & Secretary

Exhibit A

PARTNERS AND PARTNERSHIP INTERESTS

	
					
	Name and
Address of Partner
	Capital Contributions
	OP Units
	Series A 
Preferred Units
	Series B
Preferred Units

	GENERAL PARTNER:
	 
	 
	 
	 

	Invesco Mortgage Capital Inc.
	161,249,633
	1.0%
	100.0%
	0.0%

	 
	 
	 
	 
	 

	LIMITED PARTNERS
	 
	 
	 
	 

	Invesco Mortgage Capital Inc.
	2,511,803,681
	98.0%
	0.0%
	0.0%

	 
Invesco Investments (Bermuda) Ltd.
	28,500,000
	1.0%
	0.0%
	0.0%

	Total
	2,701,553,314
	100.0%
	100.0%
	0.0%

- 2 -

Exhibit F

Series B Preferred Units.  Pursuant to the authority granted under Sections 4.3.A and 4.3.B of the First Amended and Restated Agreement of Limited Partnership of IAS Operating Partnership LP (the “Partnership Agreement”), the General Partner hereby establishes a series of Preferred Units designated the 7.75% Fixed-to-Floating Series B Cumulative Redeemable Preferred Units (liquidation preference $25.00 per unit) (the “Series B Preferred Units”) on the terms set forth in this Exhibit F.  Capitalized terms used herein without definition have the meanings given to them in the Partnership Agreement.

1.Number.  The total number of authorized units of the Series B Preferred Units shall be Six Million Nine Hundred Thousand (6,900,000) and shall at all times be equal to the number of 7.75% Fixed-to-Floating Series B Cumulative Redeemable Preferred Stock, par value $0.01 per share (“Series B Preferred Stock”), issued by the General Partner and then outstanding.  Series B Preferred Units shall be issued only to and held only by the General Partner. 

2.Relative Seniority.  In respect of rights to receive distributions and to participate in distributions or payments in the event of any liquidation, dissolution or winding up of the Partnership, the Series B Preferred Units shall rank (i) on a parity with the Partnership’s 7.75% Series A Cumulative Redeemable Preferred Stock, par value $0.01 per share, and all other Units issued by the Partnership with terms specifically providing that those Units rank on a parity with the Series B Preferred Units (“Parity Units”) as to the payment of distributions and as to the distribution of assets upon liquidation, dissolution or winding up, (ii) junior to all Units issued by the Partnership with terms specifically providing that those Units rank senior to the Series B Preferred Units with respect to rights to the payment of distributions and distribution of assets upon any liquidation, dissolution, or winding up of the Partnership, and (iii) senior to all common Units issued by the Partnership and other Units issued by the Partnership other than Units referred to in clauses (i) and (ii) of this Section (b) (collectively, “Junior Units”). Nothing contained in Section 4.3.A of the Partnership Agreement or this Exhibit F shall prohibit the Partnership from issuing additional Units that are Parity Units with the Series B Preferred Units.

3.Distributions.

(a)The General Partner, as holder of the then outstanding Series B Preferred Units, shall be entitled to receive, when, as and if authorized by the General Partner and declared by the Partnership, out of any funds legally available therefor, cumulative distributions, (i) from, and including, the date of original issue date (the “Original Issue Date”) to, but excluding, December 27, 2024, at an initial rate of 7.75% of the $25.00 per share liquidation preference per unit per annum (equivalent to $1.9375 per annum per unit) and (ii) from, and including December 27, 2024, and thereafter, at a floating rate equal to three-month LIBOR (as defined below) as calculated on each applicable Date of Determination (as defined below) plus a spread of 5.18% of the $25.00 per share liquidation preference per annum.  Distributions on the Series B Preferred Units shall accrue daily and be cumulative from, and including, the date of original issue (the “Original Issue Date”) and shall be payable quarterly in arrears on the 27th day of March, June, September and December of each year (each, a “distribution payment date”); provided, that if any distribution payment date is not a business day (as defined below), then the distribution which would otherwise have been payable on that distribution payment date may be paid on the next succeeding business day with the same force and effect as if paid on such distribution payment date and no interest, additional distribution or other sums will accrue on the amount so payable for the period from and after such distribution payment date to such next succeeding business day. Any distribution payable on the Series B Preferred Units, including distribution payable for any partial distribution period, will be computed on the basis of a 360-day year consisting of twelve 30-day 

- 3 -

months (it being understood that the distribution payable on December 27, 2014 will be for more than the full quarterly period). 

(b)No distributions on the Series B Preferred Units shall be authorized by the Board or paid or set apart for payment by the Partnership at any time when the terms and provisions of any agreement of the Partnership, including any agreement relating to any indebtedness of the Partnership, prohibit the authorization, payment or setting apart for payment thereof or provide that the authorization, payment or setting apart for payment thereof would constitute a breach of the agreement or a default under the agreement, or if the authorization, payment or setting apart for payment shall be restricted or prohibited by law.

(c)Notwithstanding anything to the contrary contained herein, distributions on the Series B Preferred Units will accrue whether or not the Partnership has earnings, whether or not there are funds legally available for the payment of those distributions and whether or not those distributions are declared. No interest, or sum in lieu of interest, will be payable in respect of any distribution payment or payments on the Series B Preferred Units which may be in arrears, and holders of the Series B Preferred Units will not be entitled to any distributions in excess of full cumulative distributions described in Section 4(a).  Any distribution payment made on the Series B Preferred Units shall first be credited against the earliest accumulated but unpaid distribution due with respect to the Series B Preferred Units.

(d)Except as provided in Section 4(e), unless full cumulative distributions on the Series B Preferred Units have been or contemporaneously are declared and paid or declared and a sum sufficient for the payment thereof is set apart for payment for all past distribution periods, (i) no distributions (other than in any series of common Units (“Common Units”) or in any class or series of preferred units (“Preferred Units”) that the Partnership may issue ranking junior to the Series B Preferred Units as to distributions and upon liquidation) shall be declared and paid or declared and set apart for payment upon Common Units or Preferred Units that the Partnership may issue ranking junior to or on a parity with the Series b Preferred Units as to distributions or upon liquidation, (ii) no other distribution shall be declared and made upon Common Units or Preferred Units that the Partnership may issue ranking junior to or on a parity with the Series B Preferred Units as to distributions or upon liquidation, and (iii) no Common Units or Preferred Units that the Partnership may issue ranking junior to or on a parity with the Series B Preferred Units as to distributions or upon liquidation shall be redeemed, purchased or otherwise acquired for any consideration (or any moneys be paid to or made available for a sinking fund for the redemption of any such units) by the Partnership (except (x) by conversion into or exchange for other units of the Partnership that it may issue ranking junior to the Series B Preferred Units as to distributions and upon liquidation, and (y) for transfers made pursuant to the provisions of Article VII of the Partnership Agreement.

(e)When distributions are not paid in full (or a sum sufficient for such full payment is not so set apart) upon the Series B Preferred Units and any other class or series of Preferred Units that the Partnership may issue ranking on a parity as to distributions with the Series B Preferred Units, all distributions declared upon the Series B Preferred Units and any other class or series of Preferred Units that the Partnership may issue ranking on parity as to distributions with the Series B Preferred Units shall be declared pro rata so that the amount of distributions declared per share of Series B Preferred Units and such other class or series of Preferred Units that the Partnership may issue shall in all cases bear to each other the same ratio that accrued distributions per share on the Series B Preferred Units and such other class or series of Preferred Units that the Partnership may issue (which shall not include any accrual in respect of unpaid distributions for prior distribution periods if such Preferred Units does not have a cumulative distribution) bear to each other. No interest, or sum of money in lieu of interest, shall be payable in respect of any distribution payment or payments on the Series B Preferred Units which may be in arrears.

- 4 -

(f)“three-month LIBOR” shall mean, on any Date of Determination, the rate (expressed as a percentage per year) for deposits in U.S. dollars for a three-month period as appears on Bloomberg, L.P. page US0003M, as set by the British Bankers Association at 11:00 a.m. (London time) on such Date of Determination.  If the appropriate page is replaced or service ceases to be available, the Corporation, acting reasonably, may select another page or service displaying the appropriate rate.

(g)“Date of Determination” shall mean the second London Business Day (as defined below) immediately preceding the applicable distribution payment.

(h)“London Business Day” shall mean any day on which dealings in deposits in U.S. dollars are transacted in the London interbank market.

(i)“business day” shall mean any day, other than a Saturday or Sunday, that is neither a legal holiday nor a day on which banking institutions in New York, New York are authorized or required by law, regulation or executive order to close.

(j)Except as provided in this Exhibit F, the Series B Preferred Units shall not be entitled to participate in the earnings or assets of the Partnership.

(k)No distributions on the Series B Preferred Units shall be authorized by the General Partner or be paid or set apart for payment by the Partnership at such time as the terms and provisions of any agreement of the Partnership, including any agreement relating to its indebtedness, prohibit such authorization, payment or setting apart for payment or provide that such authorization, payment or setting apart for payment would constitute a breach thereof or a default thereunder, or if such authorization or payment shall be restricted or prohibited by law.  Notwithstanding the foregoing, distributions on the Series B Preferred Units will accrue whether or not there are funds legally available for the payment of such distributions or such distributions are authorized.

		
	4.
	Liquidation Rights.

(a)In the event of any voluntary or involuntary liquidation, dissolution or winding up of the Partnership, the holder of Series B Preferred Units will be entitled to be paid out of the assets the Partnership has legally available for distribution to owners of Units, subject to the preferential rights of the holders of any class or series of Units of the Partnership it may issue ranking senior to the Series B Preferred Units with respect to the distribution of assets upon liquidation, dissolution or winding up, a liquidation preference of Twenty-Five Dollars ($25.00) per Unit, plus an amount equal to any accumulated and unpaid distributions to, but not including, the date of payment, before any distribution of assets is made to holders of Common Units or any other class or series of Units of the Partnership it may issue that ranks junior to the Series B Preferred Units as to liquidation rights.  After payment of the full amount of the liquidating distributions provided for in this Exhibit F to the holder of the Series B Preferred Units, such holder shall have no right or claim to any of the remaining assets of the Partnership with respect to its holdings of Series B Preferred Units. 

(b)In the event that, upon any such voluntary or involuntary liquidation, dissolution or winding up, the available assets of the Partnership are insufficient to pay the amount of the liquidating distributions on all outstanding Series B Preferred Units and the corresponding amounts payable on all other classes or series of Units of the Partnership that it may issue ranking on a parity with the Series B Preferred Units in the distribution of assets, then the holders of the Series B Preferred Units and all other such classes or series 

- 5 -

of Units shall share ratably in any such distribution of assets in proportion to the full liquidating distributions to which they would otherwise be respectively entitled.

5.Redemption.  The Series B Preferred Units are not redeemable by the Partnership prior to December 27, 2024, except as described in this Section 6 and except that, as provided in the Partnership Agreement, including these terms of the Series B Preferred Units.  At any time that the General Partner exercises its right to redeem all or any of the Series B Preferred Stock of the General Partner, the General Partner shall cause the Partnership to redeem an equal number of Series B Preferred Units.  All redemptions of Series B Preferred Units shall be paid in cash at a redemption price of Twenty-Five Dollars ($25.00) per Series B Preferred Unit, plus any accumulated and unpaid distributions thereon to, but not including, the date fixed for redemption. 

6.Conversion Rights. At any time that any shares of Series B Preferred Stock of the General Partner are converted into Common Stock of the General Partner, the General Partner shall cause the Partnership to convert a number of Series B Preferred Units equal to the number of shares of Series B Preferred Stock converted into Common Stock to be converted into a number of OP Units equal to the number of shares of Common Stock into which the shares of Series B Preferred Stock were converted. 

7.Voting Rights.

(a)Except as required by law, the General Partner, in its capacity as the holder of the Series B Preferred Units, shall not be entitled to vote at any meeting of the Partners or for any other purpose or otherwise to participate in any action taken by the Partnership or the Partners, or to receive notice of any meeting of the Partners. 

8.General.  The rights of the General Partner, in its capacity as holder of the Series B Preferred Units, are in addition to and not in limitation of any other rights or authority of the General Partner, in any other capacity, under the Partnership Agreement.  In addition, nothing herein shall be deemed to limit or otherwise restrict any rights or authority of the General Partner other than in its capacity as the holder of the Series B Preferred Units.

- 6 -SETTLEMENT
AGREEMENT

 

This
Settlement Agreement (the
"Settlement Agreement") and
release of claims
is made and entered
into as of
February 23, 2015,
(the "Effective Date")
by and among
the following parties: LONZA GROUP, LTD. ("LONZA GROUP"), LONZA AMERICA,
INC. ("LAI"), LONZA WALKERSVILLE, INC. ("LWI")
(collectively "Lonza") and

AMARANTUS
BIOSCIENCE HOLDINGS, INC.,
individually and as successor
to and on behalf
of REGENICIN, INC. ("Amarantus"),
and REGENICIN, INC. ("REGENICIN")
(Lonza, Amarantus, and Regenicin collectively referred
to herein as the "Parties").

 

WHEREAS,
through its subsidiary,
Cutanogen Corporation ("Cutanogen"),
LWI is
involved in the
development of an engineered-skin-substitute
referred to at various times as "CSS",
"ESS" and/or "PermaDerm") (collectively herein referred to as
"Product"); and

 

WHEREAS,
on or about July
21, 2010, LWI
entered into a
Know-How License and Stock
Purchase Agreement ("Know-How
License") with Regenicin
pursuant to which LWI granted Regenicin
a license to use certain proprietary Product-related know how for purposes of obtaining
approval by the Food and Drug Administration,
after which Regenicin and LWI would enter into a stock purchase agreement enabling
Regenicin to acquire Cutanogen; and

 

WHEREAS,
on or about
September 30, 2013,
Regenicin commenced an
action in the Superior
Court of Fulton
County entitled, Regenicin,
Inc. v. Lonza
Walkersville, Inc., Lonza Group, Ltd. And Lonza America, Inc., Case No. 2013-CV-237150, which action
was removed to the United States District Court for the Northern District of Georgia, Case
No. 1:13-cv-3596, and thereafter
transferred to the United States District Court
for the District of New
Jersey, Case No. 1:13-cv-3596 (the
"Action"); and

 

WHEREAS,
in the Action,
Regenicin has asserted
numerous claims (the "Claims")
against Lonza, all
of which such
Claims Lonza denies
and reject as
wholly without merit; and

 

WHEREAS,
Lonza further intends
to file numerous
counterclaims against Regenicin in
the Action (the
"Counterclaims"); and

 

WHEREAS,
on or about
November 19, 2014,
Amarantus entered into
an asset purchase agreement
with Regenicin (the
"Amarantus-Regenicin APA") pursuant to which
Amarantus has now acquired, inter
alia, all of Regenicin's rights, title and
claims related to the Action, including but
not limited to the Claims, and
any and all claims Regenicin had or may have had to Lonza's and/or Cutanogen's intellectual
property, manufacturing rights, licensing rights and know-how technology; and

 

    	 

    	 

    

 

WHEREAS,
Amarantus, Regenicin and
Lonza, now desire
to settle the
Action and all Claims
and Counterclaims relating
to the Action on the terms and
conditions set forth in this Settlement Agreement; and

 

WHEREAS,
Amarantus is fully-authorized,
pursuant to the
Amarantus-Regenicin APA, to
enter into this
Settlement Agreement and
bind Regenicin to
the terms and conditions set forth
herein and Regenicin expressly acknowledges Amarantus' authority to bind Regenicin to the
terms of this Settlement Agreement.

 

NOW,
THEREFORE, in consideration
of the mutual
agreements and undertakings of
the Parties set
forth below, the Parties,
intending to be legally bound, agree and covenant as follows:

 

1.                       
Dismissal of Action.
On or before
February 26, 2015,
the Parties, by
and through their counsel
of record, shall
sign and file the Stipulation of
Dismissal with Prejudice attached hereto as Exhibit "A" and, in doing so, shall cause the Action, including
all Claims and Counterclaims that
were asserted, or could have been asserted
therein, to be dismissed with prejudice.

 

2.                        
Authority to Bind. Each
of the Parties
represents that its
undersigned representative is fully
authorized to enter
into and bind it under this Settlement.
Moreover, Amarantus hereby represents and warrants that it is fully-authorized, pursuant to the
Amarantus-Regenicin APA, to enter into this Settlement Agreement and bind Regenicin
to the terms and conditions set forth herein including, but not
limited to, the Mutual Release set forth in Section 3 and the Dismissal of the Action set forth in Section 1 hereof.

 

3.                                             
Mutual Release. In
consideration of and
subject to the
promises made in this
Settlement Agreement, Lonza,
Regenicin and Amarantus,
individually and together on
behalf of their
respective direct and indirect parent
and subsidiary companies, affiliates, predecessors (including Regenicin as a predecessor
to Amarantus), successors, assigns, and each of their respective past and present officers,
directors, stockholders, employees, agents,
heirs, executors, administrators,
insurers, attorneys, and consultants, and all persons or entities taking by, through,
or under them (each an "Affiliate" and collectively, "Affiliates"), hereby release, acquit, covenant
not to sue and forever discharge each other
and each other's Affiliates, and
their or their Affiliates' respective
directors, officers, employees, agents, attorneys, insurers,
aliases, affiliates and consultants, of and from any and all claims, counterclaims,
demands, judgments, liabilities, damages,
costs, including attorneys' fees, losses, accounts, bonds, bills, covenants, contracts,
agreements, promises, complaints, and causes of action of whatever kind or character,
whether known or unknown, at law or in equity, which Lonza,
Amarantus and/or Regenicin have, may
have, ever had, or may in the future
have against each other arising from or related to
the Action, including all Claims and Counterclaims that were asserted or could
have been asserted therein. This Mutual Release expressly includes, but
is not limited to any claims, whether known or unknown, asserted or unasserted,
relating to, (i) the Know-How License, and/or (ii) Regenicin's claim of
right, title, interest in and/or ownership of
Cutanogen and/or the Product, (iii)
the Know-How License and Stock Purchase
Agreement, dated June 30,
2009, between LWI and Vectoris Pharma
LLC (the "Vectoris Agreement")
and/or (iv) claims relating to Lonza's and/or Cutanogen's intellectual property,
manufacturing rights and know how technology; (v) claims related to Lonza's right to
any payments due from Regenicin; and/or (vi) claims for attorneys' fees and/or costs
relating to the Action, to Regenicin's Offer of Judgment filed in the Action and/or relating to the negotiation and/or
settlement of the Action. Notwithstanding the foregoing,
the Mutual Release set forth
herein shall not include
any claims Amarantus or Lonza
may have pursuant to the Option
Agreement between Amarantus ' and Lonza, as amended (the "Option Agreement").

 

    	 

    	 

    

 

4.                       
Indemnification. Amarantus shall, to
the fullest extent permitted by
law, indemnify, defend and
hold harmless Lonza
and each and
every Lonza Affiliate,
of, from and against any and all suits, actions,
legal or administrative proceedings, claims, liens, demands, damages, liabilities, losses, costs, fees (including expert
and attorney's fees) and costs of investigation, litigation,
settlement and judgment ("Indemnity Claims") directly or indirectly arising out of or
related in any way to (1) the actual
or alleged breach of Amarantus' representations, warranties or covenants contained
in this Settlement Agreement; (2) Lonza's or
any Lonza Affiliate's relationship with Regenicin or any
Regenicin alias or Affiliate including
but not limited to: Regenicin Research
of Georgia, LLC, Vectoris Pharma LLC, PharmaDerm, LLC, McCoy Enterprises and/or Randall
McCoy individually; (2) the Know-How License and/or the Vectoris Agreement and/or any services provided thereunder,
respectively; and/or (3) any actions or inaction by
Regenicin relating to Cutanogen or the Product; and/or (4) statements, representations,
filings, press releases or assertions made by Regenicin and/or Regenicin's Affiliates
regarding the Product and/or
Lonza. Amarantus, at its expense, shall assume control of the
defense and resolution of any Indemnity
Claim using legal counsel approved by Lonza and shall keep Lonza fully and timely
informed of the progress of such defense and resolution.
Lonza shall have the right to retain independent
legal counsel and monitor such Indemnity Claim's defense and resolution and Amarantus
and its counsel shall fully cooperate
with Lonza and its legal counsel in providing any information as they may request.
If both Amarantus and Lonza are named parties in
any Indemnity Claim and representation of both by the same
legal counsel would be inappropriate
due to the actual or potential conflict of
interests, then Lonza, at Amarantus' expense,
shall have the right to be represented by separate counsel of Lonza's choosing.
If Lonza, in its sole discretion, determines
that Amarantus has failed to (i) defend an Indemnity Claim to
Lonza's satisfaction or (ii) take timely
and reasonable steps to resolve an Indemnity Claim,
Lonza shall have the right,
but not the obligation, to assume control of the defense and resolution of such Indemnity Claim, and Amarantus shall be
bound by the results obtained by Lonza
with respect to the Indemnity Claim. Amarantus
shall not confess judgment or settle, compromise or resolve any Indemnity Claim without the written consent of Lonza.

 

    	 

    	 

    

 

4.                    
Attorneys' Fees 
and  Costs:  Each
of the Parties
shall bear its
own costs and 
expenses  (including  attorneys'
 fees)  in connection with 
the  Action, and the negotiation and drafting
of this Settlement Agreement. In the event
that it shall be necessary for the Parties to
initiate any action to enforce any of the terms
or provisions

contained
in this Settlement
Agreement, the prevailing
party in any such
action shall be entitled
to its reasonable costs
and attorneys' fees.

 

5.                     
No Admission
of Liability: This
Settlement Agreement shall
not be construed as an
admission of liability
by any of
the Parties as
to any Claims
or Counterclaims. The Parties acknowledge and
agree that they have
entered into this Settlement Agreement
merely to avoid the uncertainty and expense of continued litigation.

 

6.                      
Further Assurances: The Parties agree to
deliver promptly and
to execute promptly any
documents reasonably necessary
to the consummation
of the Settlement Agreement,
and to do such further acts and things as
may be necessary to carry out the intent and purposes of this Settlement Agreement.

 

7.                     
Integration: This
Settlement Agreement constitutes the
entire agreement between the
Parties regarding the
subject matter of
this Settlement Agreement,
and, except where otherwise so stated in this Settlement Agreement,
it supersedes any and all prior representations, commitments, covenants, warranties,
statements, discussions, negotiations, understandings, or agreements, either oral or written, express
or implied, regarding the subject matter of this Settlement Agreement;
provided, however, that this Settlement Agreement shall not supersede the Option
Agreement.

 

8.                      
Severability: If
any term or
provision of this
Settlement Agreement, or
the application thereof to
either Party, shall,
to any extent, be invalid or unenforceable, the remainder of this
Settlement Agreement, or the application of such term or
provision to either Party, other than those to which it is held invalid or
unenforceable, shall not be affected thereby, and each
term and provision of this Settlement Agreement shall be valid and be
enforced to the fullest extent permitted by law.

 

9.                      
Consultation With
Counsel: The Parties
represent that they
have read and understand
the meaning and
effect of this
Settlement Agreement and
that they have had an opportunity
to consult with an attorney before executing this Settlement Agreement.

 

10.                  
Mutual Preparation:
The Parties agree
that neither Party
shall be deemed to
have drafted this Settlement
Agreement. This Settlement Agreement
is the product
of the collaborative effort of the Parties and
their counsel. This Settlement
Agreement shall not be construed against either Party on
the basis that
it is the author of or
is otherwise responsible for any of the
language of this Settlement Agreement.

 

11.                  
No Modification  or
Amendment:  No modification
or amendment of
this Settlement Agreement
shall be valid or
enforceable unless agreed
to in a writing signed by each Party.

 

    	 

    	 

    

 

12.                  
No Waiver.
There shall be no
waiver of any
term or condition
absent an express writing
to that effect by
the Party to be
charged with that
waiver. No waiver of any term
or condition in this Settlement
Agreement by any Party shall be
construed as a waiver of a subsequent
breach or failure of the
same term or condition, or waiver
of any other term or condition of this Settlement Agreement.

 

13.                
Governing Law
and Forum Selection.
This Settlement Agreement
shall be interpreted, enforced
and governed by
the laws of
the State of New Jersey without regard to principles of conflict of laws.
Any and all claims relating to or arising out of this Settlement Agreement shall
be brought in a state or
federal court in New Jersey and the Parties hereby consent to
submit themselves to the jurisdiction of
such court.

 

14.                
Non-Disclosure. No
Party shall make
any disclosure to
any third parties regarding
the Action, Claims,
Counterclaims, or this
Settlement Agreement except to
the extent mutually-agreed upon by the Parties in advance of disclosure. This provision
shall not prevent any person including
the Parties, from providing testimony, other evidence, or documents if that
person is required to do so by applicable
law, rule or regulation of
a governmental authority or self-governing organization,
or otherwise by or
in connection with legal process.

 

15.                 
Specific Performance.
The Parties acknowledge
and agree that
each Party hereto will be
irreparably damaged in the
event any of the
provisions of this Agreement are not
performed by the Parties in
accordance with their specific
terms or are otherwise breached. Accordingly, it
is agreed that (a)
each of the Parties shall be entitled to specific performance of
this Agreement and its terms and provisions in any action instituted in accordance
with this Agreement and to an
injunction to prevent breaches or threatened breaches of this Agreement; (b)
no Party shall plead in defense for any such relief that there would
be an adequate remedy at law;
(c) any applicable right or
requirement that a bond be
posted by either party is waived; and (d)
such remedies shall not
be the exclusive remedies for
a breach of this Agreement, but will be in addition to all other remedies available
at law or in equity.

 

16.                 
Counterparts: This
Settlement Agreement may
be executed in
multiple counterparts, and each
executed counterpart shall
have the same
force and effect as
an original instrument, as if each of the
Parties to each counterpart had signed
the same instrument. A facsimile or scanned PDF file copy of a signature to this Settlement
Agreement shall have the same force and effect as an original signature.

 

 

[Remainder
of Page Left
Intentionally Blank]

    	 

    	 

    

 

IN
WITNESS WHEREOF, and
having read and
understood all of
the terms and conditions
of this Settlement Agreement, the
Parties have caused this Settlement Agreement to be executed as of the Effective Date.

 

LONZA
GROUP, LTD

 

By:
/s/ Authorized Signatory

Name:
Authorized Signatory

Title:
Senior Legal Counsel

 

By:
/s/ Authorized Signatory

Name:
Authorized Signatory

Title:
Senior IP Business Partner Chemicals

 

LONZA
AMERICA, INC.

 

By:
/s/ Authorized Signatory

Name:
Authorized Signatory

Title:President

 

LONZA
WALKERSVILLE, INC.

 

By:
/s/ Authorized Signatory

Name:
Authorized Signatory

Title:
President

 

AMARANTUS
BIOSCIENCE HOLDINGS, INC.

 

By: /s/
Gerald Commissiong

Name: Gerald
Commissiong

Title: President
& CEO

 

REGENICIN,
INC., by its
successor AMARANTUS BIOSCIENCE HOLDINGS,
INC.

 

By:
Gerald Commissiong

Name:
Gerald Commissiong

Title:
President & CEO

 

REGENICIN,
INC.

 

By:
/s Randall McCoy

Name:
Randall McCoy

Title:CEO

    	 

    	 

    

 

EXHIBIT
A

 

    	 

    	 

    

 

IN
THE UNITED STATES
DISTRICT COURT 

FOR
THE DISTRICT OF
NEW JERSEY

 

	REGENICIN,
                                         INC.

         

        Plaintiff,

        vs.

         

        LONZA
        WALKERSVILLE, INC., LONZA GROUP, LTD.,
        LONZA AMERICA, INC.

         

        Defendants.
	 

         

        CIVIL
        ACTION NO. 14-cv-2775

         

 

STIPULATION
OF DISMISSAL WITH
PREJUDICE

 

Plaintiff,
Regenicin, Inc. and
Defendants, Lonza Walkersville,
Inc., Lonza Group, Ltd.
and Lonza America,
Inc. ("Defendants"), pursuant
to Federal Rule
of Civil Procedure 41(a)(l)(A)(ii),
hereby file this Stipulation of Dismissal with Prejudice, dismissing
all claims with prejudice in the above-styled
action. Each of the
parties shall bear their own costs and expenses of this action.

STIPULATED
TO this _
day of, 201_.

 

 

	Ronald
                                         A. Giller

        Michael
        T. Miano

        Gordon
        & Rees, LLP

        18
        Columbia Turnpike

        Suite
        220

        Florham
        Park, NJ 07932

        Telephone:
        (973) 549-2500

        Facsimile:
        (973) 377-1911

        griller@gordonrees.com

        mmiano@gordonrees.com

        Attorney
        for Plaintiff
	Janeen
                                         Olsen Dougherty

        Grey
        Street Legal, LLC

        356
        N. Pottstown Pike,
        Ste 200

        Exton,
        PA 19341

        Telephone:
        (610) 594-4737

        Facsimile:
         (610) 594-4733 Janeen.Dougherty@greystreetlegal.com

        Attorney
        for Defendants

  

 

SO
ORDERED:

 

 

 

 

 

 __________________________

JOSEPH
E. IRENAS, U.S.D.J.

    	1

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00240-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00240-of-00352.parquet"}]]